|1.||Fukuchi, K: 4 articles (01/2001 - 02/2000)|
|2.||Nishimura, Masato: 3 articles (04/2015 - 07/2006)|
|3.||Ono, Toshihiko: 3 articles (04/2015 - 07/2006)|
|4.||Dilsizian, Vasken: 3 articles (07/2010 - 10/2005)|
|5.||Hasegawa, S: 3 articles (10/2000 - 02/2000)|
|6.||Nishimura, T: 3 articles (10/2000 - 02/2000)|
|7.||Stallings, Virginia A: 2 articles (08/2015 - 04/2013)|
|8.||Barrett, Jeffrey S: 2 articles (08/2015 - 04/2013)|
|9.||Schall, Joan I: 2 articles (08/2015 - 04/2013)|
|10.||Mascarenhas, Maria R: 2 articles (08/2015 - 04/2013)|
10/01/2006 - "To investigate whether cardiac parameters obtained by I-123 15-(p-iodophenyl)-3-methyl pentadecanoic acid (BMIPP, a radioactive fatty acid analogue) myocardial scintigraphy are useful as indicators of disease severity and predictors of cardiac events in congestive heart failure (CHF). "
07/01/1996 - "We examined the relationship between free fatty acid metabolism using 123I beta-methyl-iodophenyl-pentadecanoic acid (BMIPP) and cardiac function in patients with chronic heart failure (CHF). "
11/01/2003 - "In the present study, the effectiveness of 123I-beta-methyliodophenyl pentadecanoic acid (BMIPP) single photon emission computed tomography (SPECT) for predicting cardiac death of patients with chronic heart failure was evaluated. "
11/01/2003 - "Clinical value of iodine-123 beta-methyliodophenyl pentadecanoic acid (BMIPP) myocardial single photon emission computed tomography for predicting cardiac death among patients with chronic heart failure."
05/01/1995 - "The characteristics of myocardial fatty acid metabolism in patients with idiopathic dilated cardiomyopathy (DCM) were investigated by myocardial imaging with beta-methyl-p-[123I]iodophenyl-pentadecanoic acid (BMIPP) in 16 patients with DCM, 8 patients with hypertensive heart failure (HHF), and 11 normal subjects. "
|2.||Coronary Artery Disease (Coronary Atherosclerosis)
02/01/1998 - "[Complete absence of iodine-123 betamethyl-p-iodophenyl-pentadecanoic acid uptake in patients with suspected coronary artery disease]."
01/01/1991 - "A total of 29 patients with coronary artery disease (CAD) were investigated with 15-(p-[123I] iodophenyl)pentadecanoic acid (123I-IPPA) and sequential single photon emission tomography (SPET). "
01/01/1991 - "Single photon emission tomography imaging of myocardial oxidative metabolism with 15-(p-[123I]iodophenyl) pentadecanoic acid in patients with coronary artery disease and aorto-coronary bypass graft surgery."
07/01/2006 - "Single-photon emission computed tomography (SPECT) using a fatty acid analogue, iodine-123-beta-methyl iodophenyl-pentadecanoic acid (123I-BMIPP), as a tracer may be effective for detecting coronary artery disease in end-stage renal disease (ESRD) patients. "
08/01/1985 - "Metabolism of 15(p-123I-phenyl-) pentadecanoic acid (I-PPA) was investigated in Langendorff perfused rat hearts, fasted Wistar rats, pentobarbital-anaesthetized dogs and, in clinical studies, in patients with coronary artery disease. "
10/04/2005 - "Metabolic imaging with beta-methyl-p-[(123)I]-iodophenyl-pentadecanoic acid identifies ischemic memory after demand ischemia."
01/01/1988 - "In a canine model of reversible global ischemia, the residual quantity of 123I was assessed following a bolus injection of 15-p-(123I)-iodophenyl pentadecanoic acid (123I-IPPA). "
01/01/1988 - "Efficacy of 15-(123I)-p-iodophenyl pentadecanoic acid (IPPA) in assessing myocardial metabolism in a model of reversible global ischemia."
04/01/2007 - "This decrease of fatty acid utilization following ischemia can be imaged with fatty acid radiotracers, particularly beta-Methyl-p-(123)I-iodophenyl pentadecanoic acid (BMIPP), which demonstrates markedly limited metabolism via beta-oxidation, resulting in prolonged retention in the cardiomyocyte. "
10/04/2005 - "We hypothesized that a branched-chain fatty acid, beta-methyl-p-[(123)I]-iodophenyl-pentadecanoic acid (BMIPP), might identify the presence of myocardial ischemia late after demand ischemia at rest up to 30 hours later. "
|4.||Heart Diseases (Heart Disease)
09/01/1994 - "Heart uptake and clearance of 123I-15-(p-iodophenyl)-3(R,S)-methyl- pentadecanoic acid (BMIPP) by whole-body scintigraphy in relation to left ventricular ejection fraction (LVEF) was evaluated in 34 patients with ischaemic heart disease. "
12/01/2000 - "123I-labeled 15-(p-iodophenyl)-3R,S-methyl pentadecanoic acid (BMIPP) is a branched-chain free fatty acid that is used to evaluate various cardiac diseases. "
10/01/2011 - "123I-beta-methyl iodophenyl pentadecanoic acid (BMIPP) can visualize myocardial fatty acid metabolism and has extensive potential for diagnosing cardiac diseases such as acute coronary syndrome in the clinical setting. "
09/01/1999 - "Myocardial imaging with 123I-beta-methyl iodophenyl pentadecanoic acid (BMIPP) was performed in 28 patients with hypertrophic cardiomyopathy (HCM), 15 patients with hypertensive heart disease (HHD), 13 patients with aortic stenosis (AS) and 8 normal controls (NC). "
|5.||Chronic Kidney Failure (Chronic Renal Failure)
|2.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
|4.||omega-(4-iodophenyl)pentadecanoic acid (IPPA)
|5.||margaric acid (heptadecanoic acid)
|6.||Biological Markers (Surrogate Marker)
|8.||Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)
|9.||Technetium Tc 99m Sestamibi (Cardiolite)
|2.||Renal Dialysis (Hemodialysis)
|3.||Drug Therapy (Chemotherapy)
|5.||Angioplasty (Angioplasty, Transluminal)